Becton, Dickinson and Company (BDX), deemed a strong value, momentum, and growth stock for the long-term, is going ex-dividend soon. BDX completed the acquisition of
Critical Care from Edwards Lifescience. Numerous investment firms, including Candriam S.C.A. and Jensen Investment Management Inc, have either purchased or sold shares of BDX. The company recently encountered a 15% loss from investments a year ago.
A new President for the Life Sciences Segment, Michael Feld, has been appointed. BDX received a consensus rating of 'Moderate Buy' by brokerages. However, BDX experienced decreased short interest and shares fell due to lower-than-expected 2024 guidance.
Despite this, BDX exceeded Q2 Earnings estimates and raised fiscal 2024 guidance following the acquisition of Edwards Lifesciences' Critical Care Product Group for $4.2 billion. The company declared dividends and its stock slips on outlook. Embecta, an insulin device maker, considers a sale due to a 70% share decline after a spin-off from BDX.
Becton and Dickinson are reportedly well on their way to achieving their 2025 commitments. Additionally, according to an intrinsic calculation, BDX’s shares are 36% undervalued. Within the company’s continued growth, it surpasses Scope 1 and 2 reduction milestones for the FY 2023.
Becton Dickinson and BDX News Analytics from Wed, 08 Nov 2023 08:00:00 GMT to Sat, 07 Sep 2024 12:03:09 GMT -
Rating 6
- Innovation -2
- Information 8
- Rumor -4
